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Summary
In randomized controlled trials of patients with chronic HCV infection, elbasvir/grazoprevir (EBR/GZR) demonstrated high cure rates and a good safety profile. This study assessed the effectiveness and safety of EBR/GZR, with and without ribavirin, in a real-world HCV patient cohort. HEPA-C is a collaborative, monitored national registry Demographic, clinical and virologic data were analysed, and adverse events (AEs) recorded. A total of 804 patients were included in the study. The majority were male (57.9%), with a mean age of 60 (range, 19-92) years. Genotype (GT) distribution was GT 1, 86.8% (1a, 14.3%; 1b, 72.5%); GT 4, 13.2% and 176 patients (21.9%) were cirrhotic. Overall, among 588 patients with available data, 570 (96.9%) achieved sustained virologic response at 12 weeks post-treatment (SVR12). SVR12 rates by genotype were GT 1a, 97.7%; GT 1b, 98.6%; and GT 4, 98.1%. No significant differences in SVR12 according to fibrosis stage were observed. Eighty patients experienced an AE, resulting in treatment discontinuation in three. In this large cohort of patients with chronic HCV managed in a real-world setting in Spain, EBR/GZR achieved high rates of SVR12, comparable to those observed in randomized controlled trials, with a similarly good safety profile.
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| INTRODUC TI ON
Globally, an estimated 70 million people are chronically infected with the hepatitis C virus (HCV), with approximately 400 000 dying each year from the associated risks of infection, primarily cirrhosis and hepatocellular carcinoma (HCC).
1 Successful treatment results in a sustained virologic response (SVR), which equates with cure of HCV infection, and significantly reduces the risk of HCV-related complications, liver transplantation and death. 2, 3 However, achievement of SVR with interferon (IFN)-free direct-acting antiviral (DAA) treatment regimens, as well as IFN-containing regimens, is associated with serum increases in total cholesterol, low-density lipoprotein cholesterol (LDL-C) and plasma triglyceride (TG). 4 Although post-SVR changes in levels seem to be of the same magnitude regardless of the DAA used, significant differences in on-treatment lipid profiles have been observed. 5 The implications of changes in lipid profile on cardiovascular risk in patients infected with HCV are unknown.
In clinical trials, DAAs have achieved rates of SVR above 90%, in many cases above 95%, across all HCV genotypes. 6 Among these trials are those evaluating the efficacy and safety of a once-daily fixed-dose combination of elbasvir (EBR; 50 mg), an NS5A inhibitor, and grazoprevir (GZR; 100 mg), an NS3/4A protease inhibitor, Although clinical trials have demonstrated the efficacy and safety of EBR/GZR, their highly controlled environment and selected patient populations have the potential to limit the applicability of results to the management of patients in routine clinical practice. Therefore, the objective of this study was to evaluate the clinical effectiveness and safety of EBR/GZR in routine clinical practice in Spain.
| MATERIAL S AND ME THODS
This was a retrospective analysis of data collected prospectively in a 
| Treatment
Treatment decisions relating to the administration of the once-daily fixed-dose combination of EBR (50 mg)/GZR (100 mg), including treatment duration and the use or not of concomitant RBV, were entirely at the discretion of the treating physician based on the clinical characteristics of individual patients.
| Measurements
Demographic, clinical, virologic and safety data were collected. HCV RNA levels were determined using either the COBAS AmpliPrep 
| Statistical methods
Analyses were as described in previous studies from the HEPA-C registry on the effectiveness and safety of other oral DAA combination regimens in patients with HCV GT1 12 or GT 4 13 in routine clinical practice. Briefly, results were analysed using the intent-to- 
| RE SULTS

| Patient population
Data from 804 patients treated with EBR/GZR were analysed. The majority had HCV GT 1b infection 583/804 (72.5%) and 222/804 (27.6%) were relapsers or non-responders to previous antiviral therapy ( Of the 55 patients (8.7%) who did not achieve SVR12, 37 patients (67.3%) were lost to follow-up. All these patients had undetectable viral load at EOT. Of the 18 patients (2.9%) with virologic failure, nine (50%) experienced relapse after completion of treatment, four (22.2%) discontinued treatment voluntarily, three (16.7%) withdrew from treatment due to an AE, and two (11.1%) experienced virologic breakthrough. Among the 11 patients who relapsed or experienced breakthrough, six patients were GT 1b, four patients were GT 1a and one patient was GT 4. Mean viral load was 6.82 (SD 6.75) log 10 IU/mL and 2/11 patients (18.2%) had cirrhosis. All 11 patients were treated in accordance with the EASL guidelines; eight patients were treated with sofosbuvir/ledipasvir and three patients were treated with sofosbuvir/velpatasvir. All completed treatment.
| Clinical effectiveness
On univariate analysis, duration of treatment was significantly associated with treatment failure (P < 0.05) ( Table 3 ). None of the seven patients who discontinued therapy early achieved SVR12 and none received RBV. Among these seven patients, two had Child-Pugh A cirrhosis, three were non-responders to previous therapy, and four were treated for 12 weeks. One patient experienced virologic breakthrough on therapy.
All treatment-experienced GT 4 patients and one-third of GT 1a patients were not treated in accordance with the current EASL clinical practice guideline recommendations. 6 However, cure rates were high • Bilirubin (>2 mg/dL) • Serum albumin (<3.5 g/dL)
• Platelet count (≤70 000/mm 3 )
• Virologic response at post-treatment Week 4 (yes/no) for no response only ( Figure 2) ; in GT 1a patients, SVR12 was achieved in 100% and 98.3%
of patients with or without cirrhosis, respectively. Corresponding SVR rates in GT 4 patients were 100% and 90%, respectively.
| Safety and tolerability
Eighty AEs were reported (Table 4) , resulting in treatment discontinuation in three patients (psychiatric event, headache and rash). The most commonly reported SAEs were gastrointestinal symptoms and anaemia. The latter occurred only in patients receiving RBV. Four patients died during treatment or follow-up (two with liver cirrhosis) and one had incident hepatic decompensation (Table 4) . No clinically relevant changes in serum levels of albumin or rates of creatinine clearance were observed. Anaemia was resolved by reducing dose of RBV.
In multivariate analyses, worse creatinine clearance as measured by the Modification of Diet in Renal Disease 4-variable equation
(MDRD-4) was associated with a decreased probability of experiencing an AE (OR, 0.98; CI, 95% 0.98-0.99; P = 0.002).
| Patients with cirrhosis
Cirrhosis was present in 176 patients included in the analysis. Among the 146 of these with available data, 140 achieved SVR12 (95.9%).
There was no significant difference in SVR12 according to genotype (GT 1a, 100%; GT 1b, 97.4%; GT 4, 100% [P = 0.7]). Univariate analyses assessing association with failure to achieve SVR and occurrence of AEs are shown in Table 5 . No baseline factors were significantly associated with failure to achieve SVR12 on multivariate analysis.
In patients with cirrhosis at baseline, AEs were reported in 26/176 (14.8%). Of these, all were Child-Pugh A and six had oesoph- 
| Lipid profile
Among patients with both baseline and Week 12 post-treatment data available (n = 201), the total cholesterol levels were higher in 143 patients (73%), the LDL-C levels were higher in 153 patients (76.3%), and the HDL/LDL cholesterol ratio was lower in 141 patients (74.6%). However, the Framingham score of 10-year cardiovascular risk was only impaired in 21.4% of patients (43 patients). In addition, the Framingham score of 10-year cardiovascular risk was better in eight patients (4%) and unchanged in 150 patients (74.6%).
| D ISCUSS I ON
Our real-world study is one of the largest to date in patients with EBR/GZR is approved for use in patients infected with HCV GTs 1 and 4. 6 Recent epidemiologic data suggest that these genotypes represent 80% of cases of HCV infection in the western world.
16
Cure rates reported here are at least as high as SVR12 rates in clinical trials of 92%, 99% and 100% in treatment-naïve patients 8 and 95%, 99% and 89% in treatment-experienced patients 9 infected with HCV GTs 1a, 1b and 4, respectively.
The presence of NS5A resistance-associated substitutions (RASs) can attenuate the efficacy of DAAs, 17 particularly in some genotypes, and subtyping of HCV genotypes has proven to be of TA B L E 3 Factors associated with failure to achieve SVR on univariate analysis value due to the lower barrier to resistance of GT 1a isolates compared with GT 1b for multiple classes of DAAs. 18 Of particular relevance, SVR12 rates in GT 1a patients found to be harbouring RASs to elbasvir can be markedly reduced. 8, 9, 15 Low SVR12 rates with EBR/GZR among treatment-naïve (58%) 8 and treatment-experienced (52%) 9 GT 1a patients with NS5A RASs have been attributed to a >5-fold shift in resistance to elbasvir.
However, SVR rates of >95% in treatment-experienced patients with HCV GT 1a infection and relevant NS5A RASs treated with EBR/ GZR for 16 weeks with RBV 9 resulted in the recommendation to extend the duration of EBR/GZR treatment to 16 weeks, with the addition of RBV, in this specific population of patients.
19
In Spain, as in most countries, routine resistance testing is not performed. As a consequence, information on the presence of resistance mutations at relapse is not available for our study. The US data sheet recommends performing baseline resistance testing in all patients with GT 1a, and this approach has been shown to be costeffective compared with not testing prior to EBR/GZR treatment.
20
This recommendation is excluded from the EMA data sheet, so routine testing at baseline is not recommended in the latest EASL guidelines. 6 Indeed, it is likely that the European GT 1a differs from that present in the United States. In line with this, SVR12 rates in patients with HCV GT 1a infection were higher in our cohort (97.7%) than in the US patients (93%-95%). 8, 9 These observations could be due to the existence of two divergent clades (I and II) within GT 1a, as described recently. raised with the use of EBR/GZR in our patients and, overall, safety and tolerability, including renal safety, were good.
The rate of AEs in our study was 10%. This rate is lower than reported in previous studies 8, 9, 25 and resulted in only three patients discontinuing treatment and one case of incident decompensation in a patient with cirrhosis.
An observation that has been made in previous studies is that 
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